Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 50 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; hydrochloric acid - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - midazolam, quantity: 15 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - intravenously (iv) as an agent for: . - conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with an opioid . - induction of anaesthesia preliminary to administration of other anaesthetic agents. with the use of an opioid premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. .,intermittent iv administration or continuous infusion for: . - sedation in intensive care units, intermittent administration or continuous infusion.,intramuscularly (im) for: . - preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events

Australien - engelska - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 0.45 g - injection, solution - excipient ingredients: water for injections - the solutions are indicated for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solutions may also be used as solvents for intravenously administered drugs where compatibility has been established. 0.9% sodium chloride injection may also be used for irrigation of wounds and moistening of wound dressings. compound sodium lactate solution is particularly suitable for the replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levetiracetam, quantity: 500 mg - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium acetate trihydrate; glacial acetic acid - levetiracetam sandoz concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.,levetiracetam sandoz concentrate solution for iv infusion is indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with jme. ? add on therapy in the treatment of pgtc seizures in adults and children from 4 years of age with ige.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - albumin solution human - solution for infusion - 45mg/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - albumin solution human - solution for infusion - 45mg/1ml